Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus

Autor: Fonseca, Vivian A., Ferrannini, Ele, Wilding, John P., Wilpshaar, Wim, Dhanjal, Perminder, Ball, Greg, Klasen, Sally

Publikováno v: In Journal of Diabetes and Its Complications May-June 2013 27(3):268-273

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study

Autor: Fellström, Bengt, Zannad, Faiez, Schmieder, Roland, Holdaas, Hallvard, Jardine, Alan, Rose, Helen, Wilpshaar, Wim, Study Group, Aurora

Publikováno v: Current Controlled Trials in Cardiovascular Medicine
Current Controlled Trials in Cardiovascular Medicine, BioMed Central, 2005, 6, pp.9. ⟨10.1186/1468-6708-6-9⟩
Current Controlled Trials in Cardiovascular Medicine, Vol 6, Iss 1, p 9 (2005)

Background Patients with end-stage renal disease (ESRD) are at high risk of cardiovascular events. Multiple risk factors for atherosclerosis are present in ESRD and may contribute to the increased risk of cardiovascular mortality in this population.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b18e19723d2c81607560a5a35ae6200
https://doi.org/10.1186/1468-6708-6-9

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study.

Autor: Stalenhoef, Anton F.H., Ballantyne, Christie M., Sarti, Cinzia, Murin, Jan, Tonstad, Serena, Rose, Helen, Wilpshaar, Wim

Publikováno v: European Heart Journal; Dec2005, Vol. 26 Issue 24, p2664-2672, 9p